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To the Editors, 
We have read with great interest the recently published paper by Martinelli et al. about 
poor immunization status of children with the diagnosis of Inflammatory Bowel Disease (IBD) 
and about insufficient serological testing before starting biological therapy (1). The use of 
immunomodulators and biological therapy is associated with increased risk of opportunistic 
infections and the flare-ups of latent infections. With the increased use of these therapies, 
altered immunological status challenges physicians during the management of patients with 
IBD. 
Fortunately, guidelines and recommendations are already available relating to the 
screening and vaccination of IBD patients (2). Hungary is a positive model country in 
vaccination, as owning the first place in the “Percentage of children at 1 year of age vaccinated 
for diphtheria, tetanus and pertussis, measles and hepatitis B, 2018” list according to the OECD 
Health Statistic 2019 (3). Our strict regulation for mandatory vaccination among children could 
contribute to the later sufficient immunization and therefore to prevent new infections and avoid 
unnecessary flare-ups. Reading the disappointing results of the multicentre pediatric study, we 
would like to reveal the importance of rigorously controlled immunization status in the 
immunomodulated adult population. 
In our Centre – First Department of Medicine, University of Szeged, Hungary –, we 
routinely screen IBD patients’ immunization status before starting biological therapy. Firstly, 
we exclude the possibility of latent tuberculosis with X-ray and in case of high-risk patients, 
with the gold standard quantiferon TB test also. After that, we estimate other infections’ 
potential occurrence as well. Here, we summarize our results in respect of some vaccine-
preventable diseases and opportunistic infections. Sixty-seven IBD patients were involved in 
our analysis who started biological therapy. Forty-nine patients (73%) had seropositivity for 
Cytomegalovirus and 64 patients (95.5%) for Epstein-Bar virus infection. As expected, lower 
seroprotection rate was observed in case of Hepatitis B virus (30 patients, 44.8%), as mandatory 
vaccination against it was only initiated in 1999. Sixty-one patients (91%) had seroprotection 
for Rubella and Morbilli, both vaccines were initiated before 1999. For completeness, none of 
the patient had Hepatitis C virus infection. 
Our data highlighted that mandatory vaccination protocols beneficially effect 
seropositivity by more than 90%. In contrast, delayed regulation and consequent insufficient 
immunization can challenge the IBD centres. Therefore, every biological centre has to suit the 
following two requirements: to check the immunological status of patients who start 
immunosuppressive or biological therapy, and to be up-to-date in the current national 
vaccination guidelines. 
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